Annual General Meeting 2017

Oncopeptides Annual General Meeting to be held in the Banquet room at IVA Conference center, Grev Turegatan 16, Stockholm, Sweden, Thursday 18 May 2017 at 4.00 p.m.

Upcoming events

Webcast -- update from the ODAC meeting, Sep 22

14:00 CET

September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.

Silent Period

-

Silent Period

-

Year-end report 2022

08:00 CET